Explore Video

Dr. Enrique Grande describes case scenario of patient with prostate cancer with high volume
high grade tumor (Gleason 9, 4+5)

Toripalimab, a PD-1 inhibitor, has emerged as a promising treatment for metastatic or locally advanced recurrent NPC. Toripalimab can significantly improve response rates and prolong survival in patients who have progressed on previous therapies

Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

View comprehensive coverage of Breast Cancer from ESMO 2022

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

Summary of Key Abstracts from SABCS 2022

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

In real-world settings, Palbociclib-based combination therapy demonstrates improved progression-free survival and clinical benefit rates compared to endocrine monotherapy in HR+/HER2- advanced breast cancer.